Current breast cancer treatments can negatively affect cardiovascular health. Recently, the American Heart Association released its first scientific statement on cardiovascular disease and breast cancer. This statement includes a comprehensive overview of the prevalence of both diseases, shared risk factors, cardiotoxic effects of therapy and the prevention and treatment of cardiovascular disease in breast cancer patients. (5/2/18)
The National Comprehensive Cancer Network (NCCN) in their Survivorship Guidelines has specific recommendations related to cardiac toxicity in cancer survivors.
For patients who have received treatment with an agent linked to possible heart damage (e.g. trastuzumab, anthracyclines):
NCT02666378: Imaging Markers of Subclinical Cardiotoxicity in Breast Cancer. This research study is evaluating the use of Cardiac Magnetic Resonance Imaging (CMR) as a method of detecting early signs of damage to the heart that can be associated with anthracycline-based chemotherapy for the treatment of breast cancer.
NCT02603341: RadComp: Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial.
NCT02943590: STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines).
This research study will test whether atorvastatin, a drug commonly prescribed for reducing cholesterol levels, can protect the heart during chemotherapy with doxorubicin. Atorvastatin is from a family of medications that are commonly called "statins".
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.